

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



10/510912



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089672 A1

(51) International Patent Classification⁷: C12Q 1/70,
G01N 33/53, C12N 9/00, C07H 21/02, 21/04

Avenue, Rahway, NJ 07065-0907 (US). MURRAY, Edward, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). ZUCK, Paul, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(21) International Application Number: PCT/US03/12509

(22) International Filing Date: 11 April 2003 (11.04.2003)

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(25) Filing Language: English

(81) Designated States (national): CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(30) Priority Data:
60/372,847 16 April 2002 (16.04.2002) US

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FLORES, Osvaldo, A. [CL/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). GROBLER, Jay [US/US]; 126 East Lincoln

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEPATITIS C VIRUS ASSAY SYSTEMS

(57) Abstract: The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity

570,912



WO 03/089672 A1